Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

Fab fragment of monoclonal antibody
B3. Cancer Res 54: 3460±7.
76 Huston JS, Levinson D, Mudgett-
Hunter M et al. (1988) Protein engineering
of antibody binding sites: recovery
of specific activity in an anti-digoxin
single-chain Fv analogue produced
in Escherichia coli. Proc Natl Acad Sci
USA 85: 5879±83.
77 Bird RE, Hardman KD, Jacobson JW,
et al. (1988) Single-chain antigen-binding
proteins. Science 242: 423±6.
78 Kreitman RJ, Chang CN, Hudson DV,
Queen C, Bailon P, Pastan I (1994)
Anti-Tac(Fab)±PE40, a recombinant
double-chain immunotoxin which kills
interleukin-2-receptor-bearing cells and
induces complete remission in an in
vivo tumor model. Int J Cancer 57: 856±
64.
79 Debinski W, Pastan I (1995) Recombinant
F(ab') C242±Pseudomonas exotoxin,
but not the whole antibody-based
immunotoxin, causes regression of a
human colorectal tumor xenograft. Clin
Cancer Res 1: 1015±22.
80 Chaudhary VK, Queen C, Junghans
RP,Waldmann TA, Fitz-
Gerald DJ, Pastan I (1989) A recombinant
immunotoxin consisting of two
antibody variable domains fused to Pseudomonas
exotoxin. Nature 339: 394±7.
81 Brinkmann U, Pai LH, Fitz-
Gerald DJ,Willingham M, Pastan I
(1991) B3(Fv)±PE38KDEL, a singlechain
immunotoxin that causes complete
regression of a human carcinoma
in mice. Proc Natl Acad Sci USA 88:
8616±20.
82 Batra JK, Kasprzyk PG, Bird RE, Pastan
I, King CR (1992) Recombinant
anti-erbB2 immunotoxins containing
Pseudomonas exotoxin. Proc Natl Acad
Sci USA 89: 5867±71.
83 Kuan CT, Pastan I (1996) Improved
antitumor activity of a recombinant
anti-Lewis(Y) immunotoxin not requiring
proteolytic activation. Proc Natl
Acad Sci USA 93: 974±8.
84 Reiter Y,Wright AF, Tonge DW, Pastan
I (1996) Recombinant single-chain
and disulfide-stabilized Fv±immunotoxins
that cause complete regression of a
References
human colon cancer xenograft in nude
mice. Int J Cancer 67: 113±23.
85 Reiter Y, Pastan I (1996) Antibody engineering
of recombinant Fv±immunotoxins
for improved targeting of cancer:
disulfide-stabilized Fv±immunotoxins.
Clin Cancer Res 2: 245±52.
86 Brinkmann U, Reiter Y, Jung SH,
Lee B, Pastan I (1993) A recombinant
immunotoxin containing a disulfidestabilized
Fv fragment. Proc Natl Acad
Sci USA 90: 7538±42.
87 Glockshuber R, Malia M, Pfitzinger
I, Pluckthun A (1990) A comparison
of strategies to stabilize immunoglobulin
Fv-fragments. Biochemistry 29:
1362±7.
88 Reiter Y, Pai LH, Brinkmann U,
Wang QC, Pastan I (1994) Antitumor
activity and pharmacokinetics in mice
of a recombinant immunotoxin containing
a disulfide-stabilized Fv fragment.
Cancer Res 54: 2714±8.
89 Reiter Y, Brinkmann U, Jung SH,
Lee B, Kasprzyk PG, King CR,
Pastan I (1994) Improved binding and
antitumor activity of a recombinant
anti-erbB2 immunotoxin by disulfide
stabilization of the Fv fragment. J Biol
Chem 269: 18327±31.
90 Mansfield E, Amlot P, Pastan I, Fitz-
Gerald DJ (1997) Recombinant RFB4
immunotoxins exhibit potent cytotoxic
activity for CD22-bearing cells and tumors.
Blood 90: 2020±6.
91 Chaudhary VK, FitzGerald DJ, Pastan
I (1991) A proper amino terminus
of diphtheria toxin is important for cytotoxicity.
Biochem Biophys Res Commun
180: 545±51.
92 Chaudhary VK, Gallo MG, Fitz-
Gerald DJ, Pastan I (1990) A recombinant
single-chain immunotoxin composed
of anti-Tac variable regions and a
truncated diphtheria toxin. Proc Natl
Acad Sci USA 87: 9491±4.
93 Studier FW, Moffatt BA (1986) Use
of bacteriophage T7 polymerase to direct
selective expression of cloned
genes. J Mol Bio1 189: 113±30.
94 Kiyokawa T, Shirono K, Hattori T,
et al. (1989) Cytotoxicity of interleukin
2±toxin toward lymphocytes from pa-
373